Acurx Pharmaceuticals (ACXP) Company Report

Acurx Pharmaceuticals reported a net loss of $2 million or $1.23 per diluted share for the third quarter ended September 30, 2025, compared to a net loss of $2.8 million or $3.45 per diluted share for the same period in 2024.
The company ended Q3 2025 with cash totaling $5.9 million, an increase from $3.7 million as of December 31, 2024, and subsequently raised an additional $1.4 million from a warrant exercise in October.
Key corporate activities included a 1-for-20 reverse stock split on August 4, 2025, which resulted in regaining NASDAQ compliance on August 26, 2025, for minimum bid price and stockholder equity requirements.
Acurx also received a new Australian patent for its class of DNA polymerase 3C inhibitors and increased its total authorized shares of common stock from 200 million to 250 million.
The company is actively pursuing funding opportunities for a Phase 3 clinical trial program for ibezapolstat, which has FDA QIDP and FAST TRACK designations.

Nov 12, 2025, 1:00 PM

Acurx Pharmaceuticals Reports Q3 2025 Results and Business Update

ACXP

Earnings

Guidance Update

Delisting/Listing Issues

Acurx Pharmaceuticals reported a net loss of $2.0 million or $1.23 per diluted share for the third quarter ended September 30, 2025, an improvement from a net loss of $2.8 million or $3.45 per diluted share in the same period last year.
The company ended the third quarter of 2025 with $5.9 million in cash, compared to $3.7 million as of December 31, 2024, and subsequently received an additional $1.4 million in gross proceeds from warrant exercises in October 2025.
Acurx Pharmaceuticals regained full compliance with all Nasdaq continued listing requirements in August 2025, following a 1-for-20 reverse stock split and meeting minimum bid price and stockholders' equity thresholds.
The company's lead antibiotic candidate, ibezapolstat, is Phase 3 ready with positive regulatory guidance from both the EMA and FDA, and plans to begin international clinical trials next year, subject to obtaining appropriate financing.

Nov 12, 2025, 12:01 PM

Acurx Announces Publication of Ibezapolstat Research and Phase 3 Readiness

ACXP

New Projects/Investments

Guidance Update

Acurx Pharmaceuticals announced the publication of results from its scientific collaboration with Leiden University Medical Center (LUMC) in Nature Communications, detailing structural biology research on its lead DNA pol IIIC antibiotic, ibezapolstat (IBZ).
Ibezapolstat is an innovative new class of antibiotics targeting critical Gram-positive bacteria such as C. difficile, MRSA, VRE, and PRSP.
IBZ has demonstrated Phase 2 efficacy in treating C. difficile Infection, showing a 96% initial cure and no recurrence of infection, and is now Phase 3 ready in the U.S. and EU.
Acurx has received positive regulatory guidance from both the EMA and FDA, positioning it to commence its international Phase 3 registration program for ibezapolstat.
The company's preclinical pipeline includes an oral product candidate for ABSSSI and HAP/VAP, with a development program for inhaled anthrax also being planned.

Nov 10, 2025, 1:00 PM

Acurx Pharmaceuticals Announces New Data on DNA Pol IIIC Inhibitors at IDWeek 2025

ACXP

New Projects/Investments

Acurx Pharmaceuticals announced new data at IDWeek 2025, demonstrating a potential class effect of gut microbiome selectivity for its DNA pol IIIC inhibitor antibiotics, including its Phase 3-ready lead candidate, ibezapolstat.
This microbiome selectivity is linked to ibezapolstat's anti-recurrence effect in C. difficile Infection (CDI) patients and suggests a low probability for these inhibitors to increase the risk of causing C. difficile infection or other gut-microbiome related infections.
Ibezapolstat has previously received FDA QIDP and Fast-Track Designation, and Acurx is prepared to commence its international Phase 3 registration program with consistent regulatory guidance from both the EMA and FDA.

Oct 28, 2025, 12:00 PM

Acurx Pharmaceuticals Secures Australian Patent for DNA Polymerase IIIC Inhibitors

ACXP

New Projects/Investments

Acurx Pharmaceuticals announced that the Australian Patent Office granted a new patent for DNA Polymerase IIIC Inhibitors, which relates to compositions-of-matter and expands the company's intellectual property portfolio.
This new patent adds to Acurx's existing patents, which include three U.S. patents, one Israeli patent, one Japanese patent, and one Indian patent, all covering the ACX-375C program.
The company believes these new compounds have the potential to transform antibiotic treatment for multidrug-resistant Gram-positive pathogens such as MRSA, VRE, and PRSP, and are expected to be active against B. anthracis (anthrax).
Acurx's lead DNA pol IIIC inhibitor, ibezapolstat, is Phase 3-ready for oral treatment of C. difficile Infection, while preclinical compounds are being developed for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and inhaled anthrax.

Oct 9, 2025, 11:30 AM

Acurx Receives Positive EMA Opinion for Pediatric Investigation Plan

ACXP

New Projects/Investments

Acurx Pharmaceuticals has received a positive opinion from the European Medicines Agency's (EMA) Paediatric Committee (PDCO) on its Pediatric Investigation Plan (PIP) for ibezapolstat for C. difficile infection (CDI) in children.
This positive opinion fulfills the EMA's requirement for an agreed PIP before initiating ibezapolstat Phase 3 clinical trials in the European Union.
Ibezapolstat, a novel, orally administered antibiotic and the first of a new class of DNA polymerase IIIC inhibitors, has also received FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation, and EMA Small and Medium-sized Enterprise (SME) designation.
Successful development could lead to an additional one year of marketing exclusivity in Europe for ibezapolstat, on top of the standard 10 years for a new class of antibiotic.